At a glance
- Note: These files are not yet 508.
- Slides will be added as they become available.
June 26, 2024
Welcome & Introductions
Introduction
Dr. K Talbot, Dr. M Wharton
Respiratory Syncytial Virus Vaccines – Adult
Dr. C Kotton
Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years [17 pages]
Dr. I Munjal
Arexvy (GSK) immunogenicity with a 24-month revaccination interval [18 pages]
Dr. S Gerber
mRNA-1345 (Moderna) Update on vaccine safety, efficacy and revaccination data [24 pages]
Dr. R Das
Postmarketing safety updates: Vaccine Safety Datalink [28 pages]
Dr. J Donahue
Dr. P Lloyd
Observational RSV vaccine effectiveness [43 pages]
Dr. D Surie
Economic analysis of adult RSV vaccination [40 pages]
Dr. D Hutton
Update to benefits and risks discussion [29 pages]
Dr. D Hutton
Comparison of economic analyses of adult RSV vaccination [20 pages]
Dr. I Ortega-Sanchez
Evidence to Recommendations [114 pages]
Dr. M Melgar, L Roper, Dr. A Britton
Clinical Considerations [13 pages]
Dr. M Melgar
Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)
Dr. J Loehr
Dr. J Collins
Chikungunya Vaccine
Dr. W Chen
Update on chikungunya vaccines [3 pages]
Dr. S Hills
Epidemiology of chikungunya in U.S. territories and states [31 pages]
Dr. S Hills
Dr. K Kilburn, Dr. E Staples
Next steps for Work Group [4 pages]
Dr. S Hills
Dengue Vaccines
Dengvaxia discontinuation [4 pages]
Dr. N Bergren
Dengue vaccine updates [22 pages]
Dr. J Wong
June 27, 2024
Welcome & Introductions
Introduction
Dr. K Talbot, Dr. M Wharton
COVID-19 Vaccine
Dr. M Daley
COVID-19-associated hospitalizations [24 pages]
Dr. F Havers
COVID-19 vaccine effectiveness update [30 pages]
Dr. R Link-Gelles
Vaccine safety update for 2023-2024 COVID-19 vaccine [41 pages]
Dr. J Duffy
Economic analysis of COVID-19 vaccination [38 pages]
Dr. L Prosser
EtR for use of the 2024-2025 COVID-19 vaccine [131 pages]
Dr. L Panagiotakopoulos
COVID-19 vaccine implementation [28 pages]
Dr. S Stokley
Influenza Vaccines
Dr. J Loehr
Influenza A (H5N1) Update [16 pages]
Dr. V Dugan
WG Considerations and Proposed Recommendations [50 pages]
Dr. L Grohskopf
Pneumococcal Vaccines
Dr. J Loehr
Economic analysis and public health impact of PCV21 use in adults [45 pages]
Mr. C Stoecker
Comparison of economic analysis on PCV21 use in adults [21 pages]
Dr. A Leidner
Dr. M Kobayashi
June 28, 2024
Welcome & Introductions
Introduction
Dr. K Talbot, Dr. M Wharton
Meningococcal Vaccines
Dr. J Loehr
Epidemiology Updates [51 pages]
Ms. A Rubis
GSK Pentavalent Vaccine Immunogenicity and Safety [23 pages]
Dr. W Sohn
Dr. S Schillie
Respiratory Syncytial Virus Vaccines – Maternal/Pediatric
Dr. S Long
Implementation and uptake of nirsevimab and maternal RSV vaccine [18 pages]
Dr. S Stokley
Maternal RSV vaccine safety surveillance [26 pages]
Dr. P Moro
Summary of effectiveness of nirsevimab in infants [32 pages]
Dr. A Payne
Work Group considerations [20 pages]
Dr. J Jones, Dr. K Fleming-Dutra
Human papillomavirus Vaccines
Announcement of formation of an ACIP HPV vaccines work group [10 pages]
Dr. O Brooks